Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 3
1997 1
1998 1
2007 1
2008 1
2009 3
2010 3
2012 5
2013 4
2014 5
2015 4
2016 2
2017 1
2018 1
2019 6
2020 5
2021 5
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators. Facon T, et al. N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249. N Engl J Med. 2019. PMID: 31141632 Free PMC article. Clinical Trial.
Effet indésirable rare d’un anti-IL-1RA.
Brevet P, Curie A, Princivil C, Zarnitsky C, Boulay C, Alcaix D. Brevet P, et al. Rev Med Interne. 2020 May;41(5):343-345. doi: 10.1016/j.revmed.2019.11.008. Epub 2019 Dec 6. Rev Med Interne. 2020. PMID: 31818504 French.
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Talbot A, Bobin A, Tabone L, Lambert J, Boccaccio C, Deal C, Petillon MO, Allangba O, Agape P, Arnautou P, Belkhir R, Cailleres S, Chaoui D, Chrétien ML, Decaux O, Schulmann S, Frenzel L, Gastaud L, Huart A, Hulin C, Karlin L, Laribi K, Le Calloch R, Lenain P, Macro M, Manier S, Montes L, Moreau S, Moreau P, Morel V, Norwood J, Piocelle FO, Perrot A, Pica GM, Rey P, Schmitt A, Stoppa AM, Tiab M, Touzeau C, Vidal V, Vignon M, Vincent L, Van De Wyngaert Z, Zarnitsky C, Kerbouche N, Paka P, Leleu X, Arnulf B, Avet-Loiseau H, Du Myélome IIF. Talbot A, et al. Haematologica. 2023 Oct 1;108(10):2774-2782. doi: 10.3324/haematol.2022.281772. Haematologica. 2023. PMID: 37078253 Free PMC article.
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial.
Felten R, Devauchelle-Pensec V, Seror R, Duffau P, Saadoun D, Hachulla E, Pierre Yves H, Salliot C, Perdriger A, Morel J, Mékinian A, Vittecoq O, Berthelot JM, Dernis E, Le Guern V, Dieudé P, Larroche C, Richez C, Martin T, Zarnitsky C, Blaison G, Kieffer P, Maurier F, Dellal A, Rist S, Andres E, Contis A, Chatelus E, Sordet C, Sibilia J, Arnold C, Tawk MY, Aberkane O, Holterbach L, Cacoub P, Saraux A, Mariette X, Meyer N, Gottenberg JE. Felten R, et al. Ann Rheum Dis. 2021 Mar;80(3):329-338. doi: 10.1136/annrheumdis-2020-218467. Epub 2020 Nov 18. Ann Rheum Dis. 2021. PMID: 33208345 Clinical Trial.
Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
Mahévas T, Arnulf B, Bouaziz JD, Livideanu CB, Osio A, Servy A, Cribier B, Sassolas B, Jachiet M, Michel L, Aucouturier P, Lipsker D, Frances C, Sbidian E, Rybojad M, Descamps V, D'Incan M, Humbert P, Beylot-Barry M, Passeron T, de Moreuil C, Taha RY, Hermine O, Dupuy A, Barbarot S, Debarbieux S, Carpentier O, Brault F, Schmutz JL, Thomas-Beaulieu D, Modiano P, Zarnitsky C, Lifermann F, Baubion E, Limal N, Le Bras F, Le Moigne M, Tauber M, Talbot A, Prud'homme R, Peltier S, De Masson A, Battistella M, Bagot M, Mékinian A, Fain O. Mahévas T, et al. Blood. 2020 Apr 2;135(14):1101-1110. doi: 10.1182/blood.2019002300. Blood. 2020. PMID: 32027747 Free article.
Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission.
Kedra J, Dieudé P, Giboin C, Marotte H, Salliot C, Schaeverbeke T, Perdriger A, Soubrier M, Morel J, Constantin A, Dernis E, Royant V, Salmon JH, Pham T, Gottenberg JE, Pertuiset E, Dougados M, Devauchelle-Pensec V, Gaudin P, Cormier G, Goupille P, Mariette X, Berenbaum F, Alcaix D, Rouidi SA, Berthelot JM, Monnier A, Piroth C, Lioté F, Goëb V, Gaujoux-Viala C, Chary-Valckenaere I, Hajage D, Tubach F, Fautrel B; CRI‐IMIDIATE clinical research network. Kedra J, et al. Arthritis Rheumatol. 2024 Apr;76(4):541-552. doi: 10.1002/art.42752. Epub 2024 Jan 25. Arthritis Rheumatol. 2024. PMID: 37942714 Clinical Trial.
44 results